In Brief: Bard/Abbott
This article was originally published in The Gray Sheet
Bard/Abbott: Companies announce agreement giving Abbott Labs a semi-exclusive license to Bard's BTA bladder cancer marker. Abbott plans to "develop and market BTA tests for use in clinical laboratories" using its automated systems, according to Bard. The BTA test originally was approved by FDA in November 1995 ("The Gray Sheet" Dec. 4, p. 8). A BTA stat version, capable of providing qualitative results in five minutes, was approved by FDA in April...
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.